مباشر

Endpoints NewsPost-Hoc Live: Jeremy Levin on biotech's existential moment Endpoints NewsOutlook says FDA will sign off on its version of Avastin for wet AMD BioPharma DiveEarly data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveLilly dives into vaccine research with 3 biotech buyouts FierceBiotechMakary’s FDA reforms ‘continue to move forward’ despite leadership turmoil Clinical OMICsGPS Tracking Upends Rural Uganda’s Schistosomiasis Transmission Assumptions Endpoints NewsCartesian secures funding to 'accelerate' launch; Editas sells $125M in stock Endpoints NewsCan AI do scientific research? Billions chase hopes of superintelligence BioWorldLilly buys three vaccine makers; PCSK9 base editor shows promise BioWorldChina’s new IIT rules expected to wipe out ‘gray market’BioWorldDaewoong takes over Turn Bio’s longevity platform from Hanall BioWorldTennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline

BioWorld ٢٦ مايو ٢٠٢٦

Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline

Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based bi...

Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat H. pylori infection.